02091nam a2200361   4500001000800000005001700008007000300025008004100028040000800069041000800077100003400085245008800119300002500207520091700232650003801149650003501187650002901222650002301251650002101274700003101295700002301326700002601349700002201375700002701397700003501424700002501459700003001484700003201514700002501546773011001571942003101681999001701712ESSALUD20260820161112.0ta      t        pe ||||| |||| 00| 0 spa d  aBMG  aeng  aBhoj, Vijay G. eAutor954193  aKidney transplantation in two highly sensitized candidates after CAR T-Cell therapy  apáginas: 2117-2125  aHLA sensitization poses a major challenge to kidney transplantation for patients with end-stage kidney disease, especially for highly sensitized candidates. Attempts at antibody elimination (desensitization) have had inconsistent efficacy and have often failed to produce sustained reductions in anti-HLA antibodies in patients with the highest level of sensitization (calculated panel-reactive antibody score, ≥99.9%). We now report the results for the safety run-in cohort of a multicenter phase 1 clinical study evaluating the safety and efficacy of combined CD19-targeted and B-cell maturation antigen (BCMA)–targeted chimeric antigen receptor (CAR) T cells in eliminating the cellular sources of preformed anti-HLA antibodies (ClinicalTrials.gov number, NCT06056102). Kidney transplantation was performed in two highly sensitized candidates after desensitization with the use of dual CAR T-cell therapy.  aENFERMEDAD RENAL CRÓNICA932213  aTRASPLANTE DE RIÑÓN913898  aCIRUGÍA GENERAL944496  aCÉLULAS T954097  aTRASPLANTE97847  aKaminski, María  954194  aZhao, Huiwu954195  aJackson, Kyle 954196  aWang, Wei 954197  aLiu, Chengyang 954198  aMontgomery, Robert A.  954199  aAli, Nicole  954200  aMangiola, Massimo 954201  aSpitzer, Thomas R.  954202  aSafa, Kassem 9542030 022717922648dMassachusetts NEJM GroupoNEJM011tThe New England Journal of Medicine wESSALUDx0028-4793  cARTICULOSe2026-08-20zsqb  c22842d22842